Comparative Pharmacology
Head-to-head clinical analysis: PEPCID AC versus RANICLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID AC versus RANICLOR.
PEPCID AC vs RANICLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion.
Ranitidine is a histamine H2-receptor antagonist that competitively inhibits the action of histamine on parietal cells, thereby reducing gastric acid secretion.
20 mg orally twice daily for 12 weeks for erosive esophagitis; 20 mg orally once daily for 4-8 weeks for GERD; 10 mg orally once daily for OTC use for heartburn.
12.5 mg orally twice daily, increased to 25 mg twice daily after 2 weeks if tolerated; maximum 50 mg twice daily.
None Documented
None Documented
2.5-3.5 hours (prolonged in renal impairment, e.g., CrCl <30 mL/min: up to 20 hours)
Terminal elimination half-life: 8-12 hours (mean 10 hours) in healthy adults; prolonged in renal impairment (up to 20 hours) and elderly.
Renal (65-70% as unchanged drug), hepatic metabolism (minor), biliary/fecal (approx. 30%)
Renal: 60-70% unchanged; biliary/fecal: 20-30% as metabolites; <10% in feces as unchanged drug.
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist